Skip to main content
TECON BIOLOGY Co.LTD logo

TECON BIOLOGY Co.LTD — Investor Relations & Filings

Ticker · 002100 ISIN · CNE000001PZ9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,493 across all filing types
Latest filing 2023-06-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002100

About TECON BIOLOGY Co.LTD

https://www.tcsw.com.cn

TECON BIOLOGY Co.LTD operates an integrated industrial chain focused on animal health and nutrition. The company specializes in the research, development, and manufacturing of veterinary biological products, including a comprehensive range of vaccines and diagnostic reagents for livestock. Its operations encompass the production of high-quality animal feed and the management of large-scale breeding programs, with a primary focus on pig farming and meat processing. By leveraging advanced biotechnology and standardized production systems, the company provides comprehensive solutions for livestock management and food safety. Key activities include the formulation of specialized animal nutrition products and the implementation of rigorous biosecurity protocols across its facilities to ensure the quality and reliability of its agricultural outputs.

Recent filings

Filing Released Lang Actions
关于2023年5月份生猪销售简报
Regulatory Filings Classification · 95% confidence The document is a sales brief for May 2023 from Tian Kang Biological Co., Ltd., detailing sales volume and revenue of live pigs for that month and cumulative sales for the year to date. It includes explanations for sales changes and risk warnings. The document is short (895 characters) and provides a snapshot of sales performance rather than comprehensive financial statements or detailed analysis. It is not an annual or interim report, earnings release, or management discussion. It is a brief operational update focused on sales data for a specific month. Therefore, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into more specific categories like earnings release or interim report.
2023-06-08 Chinese
关于参加新疆辖区上市公司2023年投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Tian Kang Bio Co., Ltd. about participating in an online investor collective reception day event organized by regulatory and industry bodies. It mentions the date and time of the event and topics to be discussed, including 2022 annual performance, governance, strategy, financing plans, and sustainability. The document is short (601 characters) and serves as a notice of an upcoming investor event rather than a report or transcript. It does not contain financial statements, detailed management discussion, or voting results. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement about investor relations activities and does not fit other more specific categories.
2023-06-06 Chinese
关于天康生物股份有限公司2022年年度股东大会之法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality of the convening, attendance, and voting procedures of the 2022 Annual General Meeting (AGM) of Tian Kang Biological Co., Ltd. It details the meeting date, voting results on various agenda items including the 2022 annual report, financial statements, profit distribution plan, and other corporate matters. The document is not the AGM materials or presentations themselves but a legal opinion on the AGM process and results. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions related to the AGM proceedings. The document length is 4588 characters, which is consistent with a detailed legal opinion rather than a brief announcement. Therefore, the classification is AGM Information (AGM-R) with high confidence.
2023-05-19 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2022 Annual General Meeting (AGM) of Tian Kang Biological Co., Ltd. It includes voting results on various proposals such as the 2022 annual report, financial statements, board and supervisory reports, profit distribution plan, and other corporate matters. The document also mentions the meeting date, attendance, voting methods, and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the official voting results and decisions made at the AGM rather than the full annual report or financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-19 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司2022年度保荐工作报告
Audit Report / Information Classification · 95% confidence The document is titled as a '2022年度保荐工作报告' which translates to '2022 Annual Sponsorship Work Report' by a sponsoring institution (中信建投证券股份有限公司) for the company 天康生物股份有限公司. It details the sponsorship work overview, supervision of fundraising, governance, internal controls, and compliance with regulatory requirements. The document is a report on the sponsor's activities and findings related to the company for the year 2022. It is not an annual report (10-K), audit report, or earnings release. It is a specialized report related to sponsorship work, which aligns with the category of Audit Report / Information (AR) as it involves regulatory compliance and oversight activities but is not a full annual report. The document length is under 5,000 characters but contains substantive content, not just an announcement or certification. Therefore, the best fit is AR (Audit Report / Information). FY 2022
2023-05-12 Chinese
中信建投证券股份有限公司关于天康生物股份有限公司非公开发行股票之保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "保荐总结报告书" (Sponsorship Summary Report) issued by CITIC Securities regarding a non-public stock issuance by Tiankang Bio Co., Ltd. It details the sponsorship and continuous supervision activities related to the 2020 non-public stock issuance, including due diligence, regulatory compliance, and ongoing monitoring of fund usage. The document references regulatory frameworks and supervisory duties but does not contain financial statements or earnings data. It is a summary report related to capital raising activities, specifically a non-public stock issuance, and the role of the sponsor in overseeing this process. This fits the category of Capital/Financing Update (CAP) as it relates to updates on company fundraising and capital structure changes. The document length is 2576 characters, which is substantive and not a mere announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-05-12 Chinese

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.